Half of renally-cleared rivaroxaban is cleared as unchanged drug and half as inactive metabolites. ‡Potent inhibitors of both CYP3A4 and P-gp include azole antifungals (e.g., ketoconazole ...

1 Changshu No.2 People’s Hospital, Affiliated Changshu Hospital of Nantong University, Changshu, Jiangsu, China 2 Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University ...

In patients undergoing upper gastrointestinal endoscopic submucosal dissection, risk for ischemic stroke was lower with rivaroxaban than with dabigatran. Rivaroxaban was associated with a lower risk ...

The disciplines of pharmacology and physiology touch on virtually every field of the biomedical sciences, presenting endless opportunities to discover disease mechanisms and develop new treatments.

In the subsequent year, despite receiving adequate anticoagulation therapy with rivaroxaban, rare events of descending aortic mural thrombus and bilateral renal infarction occurred. The patient was ...

Find our full coverage below. PHILADELPHIA, PA—The novel factor XI inhibitor abelacimab, given subcutaneously once a month, is far less likely to lead to major and nonmajor clinically relevant ...

Pharmacology is a branch of biomedical science, encompassing clinical pharmacology, that is concerned with the effects of drugs/pharmaceuticals and other xenobiotics on living systems, as well as ...

Jan. 30, 2025 — Propranolol, a beta blocker medication used for treating high blood pressure and preventing migraines, may lower ischemic stroke risk in women who experience migraines ...

Many patients with NVAF are obese and manage other health conditions requiring multiple medications. This real‐world study compared health care resource use (HRU) and costs for rivaroxaban and ...

The Department of Biochemistry and Molecular Pharmacology at NYU Langone Health has a rich and distinguished history and maintains active research programs in epigenetics, genome integrity, protein ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.